Graph Therapeutics
PrivateLast Round
Early Funding
Jun 22, 2026
Total Funding Raised
$8.1M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Graph Therapeutics is a biotechnology company developing an AI-powered platform for precision drug discovery in inflammation and immunology.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Graph Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Graph Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Jun 22, 2026 | ||||
| Pre Seed | Jan 9, 2025 |
Key People
Founding team and executive leadership
Graph Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NAVEC Investment Management | Pre Seed |
| Merantix Capital | Early Funding, Pre Seed |
| Daphni | Early Funding |
| SquareOne Venture Capital | Early Funding |
| NAVEC Investment Management | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
$5M round led by Daphni
- May 7, 2025
Grew 33% QoQ from 9 to 12 employees.
Graph Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Graph Therapeutics's valuation, stock price, and market status.